By Michael Susin


Johnson & Johnson said the Canadian health authority issued a notice of compliance for its lung-cancer treatment, meaning the drug is authorized to be marketed under certain conditions.

The pharmaceutical group said Health Canada approved the use of its asset Rybrevant, in combination with chemotherapy, for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor Exon 20 insertion mutations.

The notice of compliance is based on results from a late-stage study, which demonstrated a clinically meaningful and statistically significant improvement in progression-free survival and a 60% reduction in the risk of disease progression or death compared to chemotherapy alone.

"This approval reinforces our commitment to developing novel therapies, particularly for underserved patient populations with significant unmet needs," Janssen Inc.'s President Berkeley Vincent said. Janssen Inc. is a Johnson & Johnson company.


Write to Michael Susin at michael.susin@wsj.com


(END) Dow Jones Newswires

07-03-24 0843ET